Phase 2
Capricor Therapeutics has placed a voluntary hold on its Phase II clinical trial for a Duchene Muscular Dystrophy treatment on hold after a patient experienced a severe allergic reaction during dosing.
Gossamer Bio, headquartered in San Diego, announced plans for its initial public offering (IPO) just before Christmas.
Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II ready cancer treatment from Germany-based Boehringer Ingelheim.
Favorable safety and statistically significant efficacy of oral ABX464 demonstrated in a completed randomized, double-blind, placebo-controlled induction trial based on clinical and endoscopic endpoints
Topline-data from first half of treatment period (one year)
InflaRx N.V. today announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing InflaRx to initiate a phase II study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Although Sophiris Bio plans to continue development, investors weren’t enthused, letting stock plunge more than 38 percent after the company released mixed results from its Phase IIb clinical trial of topsalysin in prostate cancer.
VAXIMM AG, announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma.
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
PRESS RELEASES